Myelofibrosis Clinical Trials in Salt Lake City, Utah

6 studies are recruiting for myelofibrosis in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

   This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   90 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT04176198 on ClinicalTrials.gov

2. AlloHCT With PegINFa for Myelofibrosis

   This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and ident…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT05535764 on ClinicalTrials.gov

3. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

   This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

   Stage

   Phase 1

   Ages

   13 and older

   Site

   University of Utah, Salt Lake City, Utah

   Locations

   8 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04771572 on ClinicalTrials.gov

4. A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

   The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assesse…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   70 in total

   Run by

   Karyopharm Therapeutics Inc

   See if you can join NCT05980806 on ClinicalTrials.gov

5. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Salt Lake City, Utah

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

6. Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

   This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in t…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah

   Locations

   215 in total

   Run by

   Kartos Therapeutics, Inc.

   See if you can join NCT06479135 on ClinicalTrials.gov